Phase 2 Study in Patients With MiT Tumors
Renal Cell Carcinoma (RCC)
Alveolar Soft Part Sarcoma (ASPS)
Clear Cell Sarcoma (CCS)
Drug: ARQ 197
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors|
- Determine the overall response rate (ORR) in patients treated with ARQ 197
- Evaluate progression-free survival (PFS) time in patients treated with ARQ 197
- Evaluate 6-month and 1-year overall survival (OS) rates in patients treated with ARQ 197
- Further characterize the safety of ARQ 197 in adolescent and young adult patients with MiT tumors
|Study Start Date:||October 2007|
|Study Completion Date:||February 2011|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Drug: ARQ 197
This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought to play multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis.
The microphthalmia transcription factor tumors (MiT tumors) are clear cell sarcoma (CCS), alveolar soft part sarcoma (ASPS), and translocation associated renal cell carcinoma (RCC). These soft tissue cancers are characterized by a common transcriptional mechanism that leads to inexorable spread and resistance to all known therapies. They tend to strike adolescents and young adults, and are invariably fatal if not resectable at diagnosis. Several academic laboratories have shown that genetic translocations in these tumors upregulate c-Met, and that such tumors are dependent upon this activity.
The study will enroll adolescent (age 13 or older) and adult patients with a histologically or cytologically confirmed MiT malignant disease. Eligible patients will receive ARQ 197 twice daily. Treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
During the study, tumor evaluations will be performed at baseline, then in 8-week intervals.
To evaluate each patient's safety and the drug's toxicity, physical examinations, laboratory evaluations, vitals signs, and adverse event assessments will be performed throughout the study. Blood samples for PK analysis will be collected during first cycle of treatment from up to 10 patients aged 20 or younger. Archival tissue specimens and relevant laboratory results on patients' gene translocation/fusion status will be collected.
Tumor biopsies may also be collected (optional) with patient's consent. If patients agree tumor samples may be collected using core needle biopsy.
In addition, to explore biological responses of tumors to ARQ 197 treatment, FDG-PET scanning will be performed at three time points: within 14 days prior to the treatment, on Day 8 (± 2 days) of Cycle 1 and after two cycles of treatment coinciding with tumor measurement.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00557609
|United States, California|
|San Francisco, California, United States, 94143|
|Santa Monica, California, United States, 90404|
|United States, Florida|
|Miami, Florida, United States, 33136|
|United States, Massachusetts|
|Boston, Massachusetts, United States, 02115|
|United States, Ohio|
|Cincinnati, Ohio, United States, 45229|
|United States, Texas|
|Dallas, Texas, United States, 75201|
|Houston, Texas, United States, 77030|
|Toronto, Ontario, Canada, M5G 2M9|
|London, United Kingdom, SW3 6JJ|